PHARMACOECONOMIC ASSESSMENT OF APIXABAN VERSUS STANDARD OF CARE FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS

被引：1

作者：

Pradelli, L. ^{[1
]}

Calandriello, M. ^{[2
]}

Di Virgilio, R. ^{[3
]}

Bellone, M. ^{[1
]}

Tubaro, M. ^{[4
]}

机构：

[1] AdRes HE&OR, Turin, Italy

[2] Bristol Myers Squibb Srl, HE OR Unit, Rome, Italy

[3] Pfizer Pharmaceut Inc, Rome, Italy

[4] San Filippo Neri Hosp, Rome, Italy

来源：

VALUE IN HEALTH | 2014年 / 17卷 / 07期

关键词：

D O I：

10.1016/j.jval.2014.08.1427

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCV83

引用

页码：A486 / A487

页数：2

共 50 条

[21] Apixaban Failure in Prevention of Ischemic Cerebrovascular Accidents in Non-valvular Atrial Fibrillation Patients
Zmaili, Mohammad
Alzubi, Jafar
Gad, Mohamed
Abu-Haniyeh, Ahmed
Saliba, Walid I.
Wazni, Oussama M.
Hussein, Ayman
CIRCULATION, 2020, 142
[22] Cost-effectiveness of Apixaban Against Dabigatran and Rivaroxaban for Stroke Prevention in Non-valvular Atrial Fibrillation Patients
Lip, Gregory Y.
Lanitis, Tereza
Kongnakorn, Thitima
Phatak, Hemant
Liu, Larry Z.
Lawrence, John
Dorian, Paul
CIRCULATION, 2014, 130
[23] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
Carla Rognoni
Monia Marchetti
Silvana Quaglini
Nicola Lucio Liberato
Clinical Drug Investigation, 2014, 34 : 9 - 17
[24] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
Rognoni, Carla
Marchetti, Monia
Quaglini, Silvana
Liberato, Nicola Lucio
CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
[25] Cost analysis: apixaban versus other anticoagulation in patients with non-valvular atrial fibrillation
Kunde, Katharina
GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2022, 27 (06): : 282 - 283
[26] NON PHARMACOLOGICAL COMPARISON OF APIXABAN VERSUS WARFARIN IN THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Vargas Zea, N.
Prieto Martinez, V
Garrido Lecca, S.
VALUE IN HEALTH, 2014, 17 (03) : A113 - A113
[27] Congress Report Stroke Prevention in non-valvular Atrial Fibrillation: Improve the Detection and Risk Assessment of Patients with Atrial Fibrillation
Uhlir, C.
JOURNAL FUR KARDIOLOGIE, 2019, 26 (5-6): : 157 - 159
[28] A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
Pinyol C.
Cepeda J.M.ª
Roldan I.
Roldan V.
Jimenez S.
Gonzalez P.
Soto J.
Cardiology and Therapy, 2016, 5 (2) : 171 - 186
[29] Antithrombotics for stroke prevention in non-valvular atrial fibrillation: an update
Berra, Kathy
EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2014, 13 (01) : 32 - 40
[30] Comparison of the Efficacy and Safety of Apixaban and Warfarin in the Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation: A Meta-Analysis
Memon, Rahat A.
Hamdani, Syed Shah Qasim
Usama, Ali
Aisha, F. N. U.
Kundi, Hayan
Mathavan, Mohit
Khalid, Malaika
Khan, Areeba
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)

← 1 2 3 4 5 →